• Injection of rAAV9 in neonatal mice exhibits high transduction patterns in the CNS.
Introduction
Adeno-associated viral (AAV) gene delivery holds great promise for treating a wide-range of neurodegenerative disorders [1] . Recombinant AAV (rAAV) vectors may be tailored for long-term, cell-type-specific transgene expression or gene knockdown with minimal cytotoxic effects [2] . AAV vectors pseudotyped with natural or engineered capsid serotypes have been used to facilitate varied transduction efficiencies and tropism throughout the nervous system [3, 4] . In recent years, AAV-mediated gene transfer has been successfully used to assess or treat preclinical models of neurodegenerative disease [5] and human clinical efficacy trials have been demonstrated for Parkinson's disease (PD) [6, 7] and Alzheimer's disease [8] .
While several AAV serotypes efficiently cross the blood-brain barrier [9] , transduction efficiency and cellular tropism is varied, making gene transfer to the nervous system a challenge. Historically, intraparenchymal injections have been the most widely used delivery routes, allowing for direct targeting of a circumscribed population of cells. This technique is particularly useful for assessing region-specific effects in adult animals, but relies on invasive, stereotaxic manipulation and is associated with limited AAV diffusion from the injection site. Recent studies have utilized the trans blood-brain barrier capacity and high transduction rate of the AAV9 serotype to facilitate widespread transgene expression throughout the nervous system by intravenous (i.v.) or intracerebroventricular (i.c.v.) injection in neonatal rodents [10] [11] [12] [13] . This combinatorial approach is increasingly used to model various neurobiological processes and as a therapeutic tool for treating neurodegeneration [14, 15] , most notably in mouse models of amyotrophic lateral sclerosis (ALS) [16] and spinal muscular atrophy (SMA) [17] [18] [19] [20] [21] [22] .
Neonatal i.v. or i.c.v. injection studies have, to date, used AAV9 vectors containing strong, ubiquitous promoters, such as cytomegalovirus (CMV), CMV/chicken ␤-actin (CMV/␤-actin), or phosphoglycerate kinase, to drive robust transgene expression. These promoters are strongly active in both neurons and nonneuronal cells, which may be advantageous for targeting non-cell autonomous toxicity [23] . However, as the utility of this technique grows, cell-type-specific transgene expression would offer a more tailored approach for modeling and targeting neurodegenerative processes. Interestingly, these promoters have helped identify an age-dependent range of AAV9 cellular tropism in neonatal mice [11, 13] ; here, reductions in neurotropism are observed in favor of astroglial transduction as early as 48 h after birth. While the reason(s) for these age-dependent variations in AAV9 tropism remain unknown, they present a challenge for cell-type-specific transduction, and, thus may limit the effectiveness of targeted therapeutics. In the present study, we use the human synapsin 1 (hSYN1) promoter to drive widespread, neuron-specific expression of green fluorescent protein (GFP) throughout the nervous system after rAAV9 neonatal i.c.v. injection.
Materials and methods

AAV9 production and preparation
Single-stranded rAAV9 viruses expressing GFP under the hSYN1 promoter (∼495 bp) and human growth hormone first (hGH) intron enhancer (AAV9-hSYN1-GFP) were produced by Virovek as previously described [24] . For neonatal injections, AAV9-hSYN1-GFP was diluted to ∼2 × 10 12 vg/mL in filtered (0.22 M) Phosphate Buffered Saline (PBS) with magnesium chloride and calcium chloride containing 0.01% FastGreen dye (Sigma-Aldrich).
Neonatal i.c.v. delivery
All animal procedures were approved by McLean Hospital's Institutional Animal Care and Use Committee. Neonatal injections were performed under cryoanesthesia as previously described [25, 26] . Pups were injected with 3.5 L AAV9-hSYN1-GFP into the lateral ventricle of each hemisphere, located 1 mm lateral to the superior sagittal sinus and 2 mm rostral to the transverse sinus, to a depth of 2 mm (Fig. 1A) . Injections were performed with a 33-gauge, 30 • beveled needle (point style 4) and gastight syringe retrofit with a Neuros adaptor and blind stop (Hamilton). Injection efficiency was monitored by dissociation of FastGreen dye throughout the lateral ventricles.
Immunofluorescence
Injected mice were terminally anaesthetized at 6 weeks-of-age with sodium pentobarbital (130 mg/kg, i.p.) and transcardially perfused with ice-cold 0.9% heparinized saline, followed by a second perfusion with 4% paraformaldehyde (PFA) in PBS. Tissues were dissected, post-fixed in 4% PFA in PBS for 6 h, and cryoprotected in 30% sucrose in PBS for storage at 4 • C. Serial sections were cut at 40 m thickness on a freezing sledge microtome or cryostat and stored in antifreeze (30% glycerol, 30% ethoxyethanol, and 40% PBS) at −20 • C. Free-floating sections were washed in PBS, blocked in 10% normal donkey serum in PBS for 1 hr at room temperature, and incubated in primary antibodies [anti-GFP (Aves Labs, 1:1000); anti-GFAP (Chemicon, 1:1000); anti-Iba-1 (Wako, 1:1000); anti-NeuN (Millipore, 1:1000); anti-peripherin (Millipore, 1:1000); anti-TH (Millipore, 1:500); anti-DARPP-32 (Cell Signaling, 1:1000); anti-ChAT (Millipore, 1:500); and anti-NF-H (Millipore, 1:500)] in blocking solution overnight at 4 • C. Sections were washed in PBS and incubated with Alexa Fluor secondary antibodies (Life Technologies, 1:300) in PBS and applied for 2 h at room temperature. For detection of gastrocnemius neuromuscular junctions (NMJs), ␣-bungarotoxin conjugated to tetramethylrhodamine (Life Technologies, 1:500) in PBS was applied at this step. Sections were washed in PBS and coverslipped on slides with aqueous mounting media. High magnification fluorescent images are presented as 10-15 M z-stacks taken with a Zeiss LSM 510 Confocal Microscope (Carl Zeiss), while whole brain and spinal cord images were captured at 4× magnification and stitched together with a Keyence BZ-9000 Fluorescence Microscope (Keyence).
Immunoblotting
Injected mice were terminally anaesthetized at 6 weeks-of-age with sodium pentobarbital (130 mg/kg, i.p.) and transcardially perfused with ice-cold 0.9% heparinized saline. Select brain sections were immediately dissected using a McIlwain Tissue Chopper (Ted Pella), while the spinal cord, DRG, and gastrocnemius muscle were removed intact. Tissues were homogenized in 2% sodium dodecyl sulfate (SDS) in PBS containing 1× HALT Protease Inhibitors (Pierce Biotechnology) and boiled for 5 min. Protein samples (10-15 g) were separated on Criterion 4-15% SDS polyacrylamide gels (BioRad) and transferred to polyvinyldifluoride membrane. Membranes were blocked with 5% skim milk in Tris-buffered saline containing 0.2% Tween-20 for 1 h at room temperature, then incubated in primary antibodies [anti-GFP (Aves Labs, 1:2500) and anti-NSE (Abcam, 1:5000)] in blocking solution overnight at 4 • C. Antibody binding was revealed using horseradish peroxidase conjugated IgG and visualized by chemiluminescence using the ChemiDoc XRS+ (Bio-Rad).
Quantification
Viral transduction was quantified from brain regions corresponding to anterior-posterior coordinates relative to Bregma [27] : motor and somatosensory cortex (layer V) and dorsolateral and ventromedial striatum, 0.9-0.7 mm; hippocampus (CA1), −2.2 to −2.4 mm; substantia nigra pars compacta and reticulata, −3.0 to −3.3 mm; cerebellum (central or ansiform lobes), −6.1 to −6.5 mm. For spinal cord, the ventral horns of well-transduced cervical and lumbar sections were quantified. Anti-NeuN was used to identify neurons, except for the cerebellum and muscle, where NF-H and ␣-bungarotoxin were used, respectively. We performed simple immunofluorescent counts using StereoInvestigator software (MBF Bioscience). Neuronal transduction rates (presented as mean ± S.E.M; n = 6-13) were calculated by dividing the number of NeuN-or NF-H-positive neurons expressing GFP by the total number of NeuN-or NF-H-positive neurons from z-stack projections of the aforementioned brain and spinal cord regions. Similar counts were performed to evaluate transduction rates in DARPP-32-, TH-, or ChAT-positive cells (n = 3). Western blot images were analyzed by ImageJ (NIH) using the integrated density function after background subtraction (n = 6); here, the values representing each GFP band were divided by the values of the corresponding NSE loading control to obtain relative protein expression.
Results
The lateral ventricles of P2 neonatal mice were injected with 3.5 L of ∼2 × 10 12 vg/mL AAV9-hSYN1-GFP per hemisphere (Fig. 1A) . The rAAV9 vector contains the hSYN1 promoter and hGH first intron enhancer upstream of the GFP open reading frame (Fig. 1B) . We previously used the hSYN1 promoter to drive neuronspecific transgene expression in the substantia nigra of adult rats after intraparenchymal injection with rAAV2 [28] . In the current study, widespread GFP expression was observed throughout the CNS, including the forebrain, midbrain, hindbrain, and spinal cord 6 weeks after injection (Fig. 1C) . At higher magnification, neuronspecific GFP expression was identified from its co-localization with NeuN in the motor cortex (Fig. 1D/D ) , hippocampus ( Fig. 1E/E ) , striatum ( Fig. 1F/F ), substantia nigra ( Fig. 1G/G ) , cerebellum ( Fig. 1H/H ) , and spinal cord (Fig. 1I/I ). NF-H was used as the neuronal marker in the cerebellum (not shown), where the anti-NeuN antibody does not recognize some neurons. GFP immunoreactivity was not observed in the cortex when injected with FastGreen dye only (Fig. 1J /J and C, back image). GFP expression was observed only in NeuN-or NF-H-positive cells and not in astrocytes or microglia, which were identified by anti-GFAP (Fig. 1K, arrowheads) and anti-Iba-1 (Fig. 1L, arrowheads) antibodies, respectively. Neuronal transduction rates (mean ± S.E.M; n = 6-13), quantified from specific regions, were as follows: 43.5 ± 3.3% and 32.4 ± 3.7% in the motor and somatosensory cortices, respectively; 43.1 ± 2.7% in the hippocampus; 16.8 ± 4.5% and 16.9 ± 4.3% in the dorsolateral and ventromedial striatum, respectively; 22.5 ± 4.2% and 45.9 ± 5.4% in the substantia nigra pars compacta and reticulata, respectively; 29.6 ± 2.3% in the cerebellum; and 24.9 ± 3.9% and 20.9 ± 2.6% in the ventral horns of the cervical and lumbar spinal cord, respectively (Fig. 1M) . Region-specific transgene expression was further analyzed by immunoblotting (Fig. 1N) . Densometric analysis of GFP expression, relative to the neuron-specific reference protein, NSE, revealed differences among the regions examined (n = 6). The order of GFP expression among these regions, from highest to lowest, were as follows: hippocampus > cortex > striatum > ventral midbrain > cerebellum > lumbar spinal cord > cervical spinal cord (Fig. 1O) .
We identified that AAV9-hSYN1-GFP neonatal i.c.v. injections showed neuron-specific GFP expression in the PNS. GFP expression was observed in DRG neurons ( Fig. 2A/A ) and in nerve bundles of the sciatic nerve (Fig. 2B/B ) . GFP immunoreactivity was further observed in 14.6 ± 2.2% of NMJs in the gastrocnemius muscle, which were identified by staining with ␣-bungarotoxin (Fig. 2C,  arrowheads) , and along the length of their innervating axons (Fig. 2C, arrows) . The surrounding muscle cells did not show GFP immunoreactivity.
Given the widespread neuron-specific transduction pattern associated with AAV9-hSYN1-GFP neonatal i.c.v. injection, we looked at whether GFP was expressed in neuronal sub-types relevant to some neurodegenerative diseases, including Huntington's disease (HD), PD, and ALS. GFP expression co-localized with DARPP-32-positive medium spiny neurons in the ventromedial striatum (Fig. 3A, upper panel, arrowheads) , TH-positive dopaminergic neurons in the substantia nigra pars compacta (Fig. 3A, middle panel,  arrowheads) , and ChAT-positive motor neurons in the lumbar spinal cord (Fig. 3A, lower panel, arrowheads) . Here, transduction rates (n = 3) were as follows: 11 ± 2.1% of DARPP-32 neurons; 15.9 ± 3% of TH neurons; and 40.8 ± 7.3% of ChAT neurons (Fig. 3B ).
Discussion
Neonatal i.v. or i.c.v. gene transfer using AAV9 vectors is growing in popularity due to the unprecedented rates of transgene expression obtained in the adult nervous system. This is largely due to AAV9's higher transduction rates and more widespread biodistribution [2, 29, 30 ] when compared to other serotypes that also cross the blood-brain barrier [9, 13] . An interesting finding to emerge from AAV9 neonatal injections was that neurons, astrocytes, and vascular endothelia are transduced at varying degrees throughout the nervous system [11] . The viral-receptor mechanisms underlying these transduction patterns remain unknown, but, in general, greater neurotropism is observed for injection at P0-1, while enhanced astrocytic tropism is observed for injections at P2 and older [13] . Other explanations may also account for these age-dependent changes, including route of administration, viral titer and purification, and AAV diffusion, but because these studies employed the use of general promoters, such as CMV and CMV/chicken-␤-actin, transgene expression may occur in a noncell-specific manner [31] . We previously used the hSYN1 promoter to drive rAAV2-mediated expression of human mutant ␣-synuclein into the substantia nigra of rats in a model of ␣-synucleinopathy in PD [28] . In that study, the hSYN1 promoter offered strong, protracted neuron-specific activity up to 17 weeks, whereupon the rats were sacrificed due to significant dopaminergic neuron loss associated with disease. Others have reported hSYN1 promoter-driven expression after 2.5 and 9 months in vivo after intraparenchymal injection using lentiviral or adenoviral vectors, respectively [32, 33] . In the current study, we show that the hSYN1 promoter can be used with rAAV9 to achieve high neuron-specific transduction rates in the CNS and in sciatic nerve, DRG, and NMJs after neonatal injection at P2, an age associated with preferential astrocytic tropism [13] . While neonatal i.c.v. injections with rAAV9 using general promoters are associated with varied cellular tropism, and hence some neuronal expression is expected, we did not observe GFP expression in astrocytes or microglia, thus demonstrating that the hSYN1 promoter confers neuronal specificity. The transduction rates reported here are appreciable when compared to other AAV9 studies, but since the methodological approach to gene transfer often differs (serotype, promoter, injection route, etc.), direct comparisons among these studies are difficult. Despite this, a similar approach to the current study was recently reported by Dirren and colleagues, who used the minimal glial fibrillary acidic protein promoter (gfaABC1D) to restrict expression to astrocytes [34] , thus highlighting the growing interest in cell-type specific expression after neonatal injection.
Neonatal i.v. and i.c.v. injections using rAAV9 are increasingly used to model or treat neurodegenerative disease in rodents, notably for the motor neuron diseases, ALS and SMA. A rat model of ALS was recently created by i.v. delivery of rAAV9 expressing human TDP-43 and a pathological fragment, TDP-25, emulating the phenotype observed in TDP-43 transgenic models [35, 36] . In the mutant (G93A) human superoxide dismutase (SOD1) mouse model of ALS, increased survival and reduced disease progression were observed after neonatal i.v. injection of rAAV9 encoding shRNA targeting human SOD1 [16] . In the SMN 7 and SMN2 mouse models of SMA, dramatic extensions in survival and motor function were demonstrated after neonatal i.v. or i.c.v. delivery of exogenous survival motor neuron protein (SMN) [17] [18] [19] [20] [21] [22] . Interestingly, gene therapy in SMA mice was associated with survival variability when the rAAV9 was injected at different postnatal ages [18, 21] . Given that age-dependent differences in cellular tropism are associated with AAV9 neonatal injection, this suggests that cell-type-specific targeting may be important for effective gene therapy during narrow therapeutic windows. Another point to emerge from rAAV9-mediated gene therapy in SMA mice was that i.c.v. injections were associated with longer survival than i.v. injections [19] , suggesting that, in some models, restriction of rAAV9 within the nervous system may be beneficial. Although the use of general promoters may be helpful for global gene targeting, celltype-specific promoters may help tailor this expression to augment therapeutic potential. In the current study, we show GFP expression in DARPP-32-positive medium spiny neurons of the striatum, THpositive neurons of the substantia nigra, and ChAT-positive motor neurons of the spinal cord, which are vulnerable neuronal populations in HD, PD, and ALS, respectively. Future studies will warrant the examination of cell-type specific promoters with different serotypes and delivery routes. For example, Levites and colleagues utilized the strong transduction capacity of AAV1-CMV/␤-actin to deliver recombinant anti-A␤ single-chain variable fragments to P0 CRND8 transgenic mice in an anti-A␤ immunotherapy model of Alzheimer's disease [37] . In addition, the development of neuron-specific shRNA promoters, for example, a hybrid between hSYN1 and polymerase III U6/H1 promoters, would significantly aid current gene therapy studies using RNAi. Because these diseases are associated with non-cell autonomous toxicity to some degree [23] , the use of cell-type-specific promoters to overexpress or knockdown genes-of-interest will help identify disease-related processes and/or refine prospective therapies.
